Healio Psoriatic Disease Current Issue
The following articles appeared in the print edition of Healio Psoriatic Disease.
Table of Contents
- A Mainstay in Psoriasis Treatment, Phototherapy Remains Relevant
-
- FDA approves Vtama for topical psoriasis treatment Rebecca L. Forand
- Psoriatic arthritis trials should seek deeper remission states, end placebo controls Erich Martin
- Q&A: Identifying, Treating Rare Mucosal Melanoma
- Ustekinumab biosimilar candidate achieves ‘therapeutic equivalence’
- Narrowband UVB Phototherapy Another Vital Component to Psoriasis Treatment Joel M. Gelfand, MD, MSCE
- EULAR: Routine, proactive therapeutic drug monitoring unnecessary in RMDs Erich Martin
- Ixekizumab’s safety profile ‘reassuring’ after 3-year follow-up in psoriatic arthritis Erich Martin
- ‘Large proportion’ of patients with PsA fail to meet treatment targets Erich Martin
-
- Oral TYK2 inhibitor shows promise in plaque psoriasis Rebecca L. Forand
- Apremilast could lower cardiometabolic risk in psoriasis patients Rebecca L. Forand
- Growing psoriatic arthritis armamentarium can target specific disease domains Rob Volansky
- Real-world results show tildrakizumab’s efficacy in psoriasis Rebecca L. Forand
- Rheumatologists at ‘forefront’ of diagnosing scleroderma skin disease Rob Volansky